Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2024-10-10
Completion Date
2026-08
Last Updated
2024-10-21
Healthy Volunteers
No
Interventions
SSGJ-707
SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
carboplatin
chemotherapy
paclitaxel
chemotherapy
Locations (1)
Chongqing Cancer Hospital
Chongqing, China